AVTE
Price:
$2.56
Market Cap:
$73.92M
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2021-06-30
Stock Exchange
NASDAQ
Ticker
AVTE
According to Aerovate Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 43.34M. This represents a change of -88.43% compared to the average of 374.64M of the last 4 quarters.
The mean historical Enterprise Value of Aerovate Therapeutics, Inc. over the last ten years is 522.39M. The current 43.34M Enterprise Value has changed 729.72% with respect to the historical average. Over the past ten years (40 quarters), AVTE's Enterprise Value was at its highest in in the March 2024 quarter at 846.37M. The Enterprise Value was at its lowest in in the June 2021 quarter at -53600574.92.
Average
522.39M
Median
556.28M
Minimum
234.18M
Maximum
695.73M
Discovering the peaks and valleys of Aerovate Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 197.10%
Maximum Annual Enterprise Value = 695.73M
Minimum Annual Increase = -57.63%
Minimum Annual Enterprise Value = 234.18M
Year | Enterprise Value | Change |
---|---|---|
2023 | 573.05M | -17.63% |
2022 | 695.73M | 197.10% |
2021 | 234.18M | -57.63% |
2020 | 552.72M | -0.64% |
The current Enterprise Value of Aerovate Therapeutics, Inc. (AVTE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
500.99M
5-year avg
522.39M
10-year avg
522.39M
Aerovate Therapeutics, Inc.’s Enterprise Value is greater than Adagene Inc. (8.35M), less than Acrivon Therapeutics, Inc. Common Stock (158.62M), less than Rezolute, Inc. (248.88M), greater than AN2 Therapeutics, Inc. (8.33M), greater than Anebulo Pharmaceuticals, Inc. (31.01M), less than Opthea Limited (552.48M), less than Mineralys Therapeutics, Inc. (502.94M),
Company | Enterprise Value | Market cap |
---|---|---|
8.35M | $83.23M | |
158.62M | $198.03M | |
248.88M | $257.27M | |
8.33M | $41.83M | |
31.01M | $32.42M | |
552.48M | $4.57B | |
502.94M | $600.21M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aerovate Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aerovate Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Aerovate Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Aerovate Therapeutics, Inc. (AVTE)?
What is the 3-year average Enterprise Value for Aerovate Therapeutics, Inc. (AVTE)?
What is the 5-year average Enterprise Value for Aerovate Therapeutics, Inc. (AVTE)?
How does the current Enterprise Value for Aerovate Therapeutics, Inc. (AVTE) compare to its historical average?